Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter C Lucas

Showing results (61-70 of 118) with videos related to

Pageof 12
Sort By:
Cancer Cell|August 4, 2009
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorderKatherine I Oravecz-Wilson, Steven T Philips, Omer H Yilmaz, et al.
Science (New York, N.Y.)|January 29, 2011
Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activationShaun Rosebeck, Lisa Madden, Xiaohong Jin, et al.
Cell Reports|June 19, 2012
Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistanceMatthew Van Beek, Katherine I Oravecz-Wilson, Phillip C Delekta, et al.
Plos One|August 18, 2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutationsRekha Pal, Ning Wei, Nan Song, et al.
Cancer Letters|June 24, 2019
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinomaLan Cao, Ahmed Basudan, Matthew J Sikora, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Identification of tumor-intrinsic drivers of immune exclusion in acral melanomaRyan C Augustin, Sarah Newman, Aofei Li, et al.
Breast Cancer Research : BCR|February 10, 2019
Targeted mutation detection in breast cancer using MammaSeq™Nicholas G Smith, Rekha Gyanchandani, Osama S Shah, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 3, 2009
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistDaniel R Rhodes, Bushra Ateeq, Qi Cao, et al.
Molecular Cancer Research : MCR|November 10, 2021
MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast CancerJia-Ying Lloyd Lee, Prasanna Ekambaram, Neil M Carleton, et al.
JNCI Cancer Spectrum|August 11, 2021
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical PracticeAlexander H G Paterson, Peter C Lucas, Stewart J Anderson, et al.
Pageof 12

Showing results (61-70 of 118) with videos related to

Sort By:
Pageof 12
Cancer Cell|August 4, 2009
Persistence of leukemia-initiating cells in a conditional knockin model of an imatinib-responsive myeloproliferative disorderKatherine I Oravecz-Wilson, Steven T Philips, Omer H Yilmaz, et al.
Science (New York, N.Y.)|January 29, 2011
Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activationShaun Rosebeck, Lisa Madden, Xiaohong Jin, et al.
Cell Reports|June 19, 2012
Bcl10 links saturated fat overnutrition with hepatocellular NF-kB activation and insulin resistanceMatthew Van Beek, Katherine I Oravecz-Wilson, Phillip C Delekta, et al.
Plos One|August 18, 2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutationsRekha Pal, Ning Wei, Nan Song, et al.
Cancer Letters|June 24, 2019
Frequent amplifications of ESR1, ERBB2 and MDM4 in primary invasive lobular breast carcinomaLan Cao, Ahmed Basudan, Matthew J Sikora, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Identification of tumor-intrinsic drivers of immune exclusion in acral melanomaRyan C Augustin, Sarah Newman, Aofei Li, et al.
Breast Cancer Research : BCR|February 10, 2019
Targeted mutation detection in breast cancer using MammaSeq™Nicholas G Smith, Rekha Gyanchandani, Osama S Shah, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 3, 2009
AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonistDaniel R Rhodes, Bushra Ateeq, Qi Cao, et al.
Molecular Cancer Research : MCR|November 10, 2021
MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast CancerJia-Ying Lloyd Lee, Prasanna Ekambaram, Neil M Carleton, et al.
JNCI Cancer Spectrum|August 11, 2021
<i>MAF</i> Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical PracticeAlexander H G Paterson, Peter C Lucas, Stewart J Anderson, et al.
Pageof 12